The Oncology Central newsletter appeared
in my in-box today. Much of it was over my head, but some of it will probably
stick…
 |
Editor's pick |
.png?width=520&upscale=true&name=OC%20NL%20(20).png) |
US FDA drug approvals in oncology: the latest news
Our drug approvals round-up is here! Explore two newly approved drugs, Elrexfio™ used to treat multiple myeloma and Akeega™ used to combat BRCA-positive metastatic castration-resistant prostate cancer. |
Latest articles |
 |
Gut feeling: AI tool predicts stomach cancer risk up to 3 years prior to diagnosis
AI successfully uses demographic information, medical history and routine laboratory findings to predict a patient’s risk of developing esophageal cancer up to 3 years before diagnosis. Read the full story here >> |
 |
Sacroiliitis in cancer patients: a review of current literature
To understand how cancer and cancer therapy pose additional risks to the development of sacroiliitis joint pain, read this literature review from Pain Management. |
 |
Anxiety medication linked to worse outcomes for pancreatic cancer patients
Benzodiazepine lorazepam, a drug prescribed to treat anxiety during cancer treatment, has been associated with shorter progression-free survival rates in patients suffering from pancreatic cancer. Read the full story in our latest news article >> |
No comments:
Post a Comment